A Study to Extend Efficacy and Safety of SHR-1819 Injection in Adult Patients With Moderate to Severe Atopic Dermatitis

PHASE2Enrolling by invitationINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions

Moderate to Severe Atopic Dermatitis

Interventions

DRUG

SHR-1819 injection

SHR-1819 injection 300 mg Q2W

Trial Locations (1)

Huashan Hospital,Fudan University, Shanghai

All Listed Sponsors

lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY